Gapping down
In reaction to disappointing earnings/guidance: ICLD -9%, OPXA -7.8%, PIH -5.7%, PCTY -4.6%, JD -4.4%, JWN -4%, XGTI -3.9%, WB -3.1%, EXTR -1.9%.
Other news: NQ -15.8% ( announces management changes; CFO has resigned from his position for family reasons effective Aug 22, 2014), IDCC -6.7% (co announced it is disappointed with decision by the U.S. International Trade Commission to terminate Investigation No. 337-TA-868), NWBO -5.1% (announced pricing of $17.5 mln offering of convertible notes; convertible at $7.30/share; will fund new manufacturing capacity in Europe), CNAT -3.3% ( filed for a $150 mln mixed securities shelf offering), NEO -2.7% (announced public offering of common stock; size not disclosed), MASI -1.7% (disclosed it received a warning letter from the U.S. FDA regarding compliance with current Good Manufacturing Practices at Masimo's Irvine, CA manufacturing facility.), ZGNX -1.5% (disclosed it received a paragraph IV certification from Actavis (ACT) advising of the filing of an ANDA for a generic version of Zohydro).
Analyst comments: ICPT -2.1% (initiated with a Underperform at FBR Capital; tgt $172 ), KKR -1% (downgraded to Market Perform from Outperform at Wells Fargo), BEBE -0.7% (downgraded to Neutral from Buy at Janney).
In reaction to disappointing earnings/guidance: ICLD -9%, OPXA -7.8%, PIH -5.7%, PCTY -4.6%, JD -4.4%, JWN -4%, XGTI -3.9%, WB -3.1%, EXTR -1.9%.
Other news: NQ -15.8% ( announces management changes; CFO has resigned from his position for family reasons effective Aug 22, 2014), IDCC -6.7% (co announced it is disappointed with decision by the U.S. International Trade Commission to terminate Investigation No. 337-TA-868), NWBO -5.1% (announced pricing of $17.5 mln offering of convertible notes; convertible at $7.30/share; will fund new manufacturing capacity in Europe), CNAT -3.3% ( filed for a $150 mln mixed securities shelf offering), NEO -2.7% (announced public offering of common stock; size not disclosed), MASI -1.7% (disclosed it received a warning letter from the U.S. FDA regarding compliance with current Good Manufacturing Practices at Masimo's Irvine, CA manufacturing facility.), ZGNX -1.5% (disclosed it received a paragraph IV certification from Actavis (ACT) advising of the filing of an ANDA for a generic version of Zohydro).
Analyst comments: ICPT -2.1% (initiated with a Underperform at FBR Capital; tgt $172 ), KKR -1% (downgraded to Market Perform from Outperform at Wells Fargo), BEBE -0.7% (downgraded to Neutral from Buy at Janney).